Advertisement Medicyte, Primacyt receive BMBF grant to develop human liver cells - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Medicyte, Primacyt receive BMBF grant to develop human liver cells

Medicyte and Primacyt have received a grant of EUR300,000 grant from the Federal Ministry of Education and Research (BMBF) to develop culturing methods of human hepatocytes for use in cell-based therapies.

Medicyte is a company involved in the generation of human primary cells based on the upcyte technology, while Primacyt is a firm involved in long-term culturing of primary human hepatocytes.

Medicyte’s upcyte technology enables the expansion of human primary liver cells to large amounts and with consistent quality.

Primacyt is capable of serum-free, long-term culturing of primary human hepatocytes and the development of cell culture media.

Both companies now combine their knowledge to develop modified liver cells in large amounts for use in cell-based therapies.

Medicyte managing director and CSO Braspenning said this collaboration will result in a vast pool of scientific data that support upcyte as enabling technology of great value.

Primacyt managing director Runge said the application and development of improved in-vitro systems for the treatment of severe liver disease is a key area of focus of their research and they believe the partnership with Medicyte and the University of Tübingen will be ideal to improve bioartificial liver devices.

Led by Prof. Andreas Nüssler, the three-year project is supported by a team from the University of Tübingen.